Clincosm LogoSign in Get a demo

DLBCL

Showing NaN - NaN of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NHL, DLBCL, Non-hodgkin's Lymphoma Trial in United Kingdom, United States (AZD9150, Acalabrutinib, AZD6738)

Completed
  • NHL
  • +3 more
  • Los Angeles, California
  • +11 more
Aug 11, 2022

DLBCL Trial in United States (MB-CART2019.1)

Recruiting
  • DLBCL
  • MB-CART2019.1
  • Gilbert, Arizona
  • +14 more
Jun 17, 2022

Advanced Solid Tumor, NSCLC, Melanoma Trial in United States (AB308, Zimberelimab)

Recruiting
  • Advanced Solid Tumor
  • +9 more
  • Phoenix, Arizona
  • +20 more
May 2, 2022

Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
Mar 7, 2022

DLBCL, Lymphoma, B-Cell Trial in Rochester (Polatuzumab vedotin, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL
  • Lymphoma, B-Cell
  • Polatuzumab vedotin
  • +4 more
  • Rochester, New York
    University of Rochester
Jan 6, 2022

DLBCL, Richter Syndrome Trial in United Kingdom, United States (acalabrutinib, vistusertib)

Terminated
Has Results
  • DLBCL
  • Richter Syndrome
  • Fairway, Kansas
  • +10 more
Jan 4, 2021

Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma Trial in United States (SGN-CD19B)

Terminated
  • Non-Hodgkin Lymphoma
  • +3 more
  • Birmingham, Alabama
  • +15 more
Aug 9, 2018

Advanced Cancers, DLBCL, Lymphoma Trial in United States (IONIS-STAT3Rx)

Completed
  • Advanced Cancers
  • +2 more
  • Scottsdale, Arizona
  • +8 more
Jun 20, 2018